Drug Profile

Testosterone topical - Ferring Pharmaceuticals

Alternative Names: FE-999303; Testarzon; Testavan; Testavance

Latest Information Update: 04 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ferring Pharmaceuticals
Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
Mechanism of Action Androgen receptor agonists; Testosterone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Hypogonadism

Most Recent Events

04 Dec 2025 Launched for Hypogonadism in Norway, Ireland, Belgium, Italy (Topical), prior to December 2025
19 Jun 2025 Launched for Hypogonadism in Denmark (Topical)
25 Feb 2021 Discontinued - Phase-III for Hypogonadism in Canada (Topical)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com